CG Oncology Inc (CGON) 뉴스

CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing...

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette...

Form 8-K - Current report

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of...

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form EFFECT - Notice of Effectiveness

CG Oncology Announces Pricing of Public Offering

IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical...